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Background: Surveillance of drug quality for antibiotics, antiretrovirals, antimalarials and vaccines is better established
than surveillance for maternal health drugs in low-income countries, particularly uterotonic drugs for the prevention
and treatment of postpartum hemorrhage. The objectives of this study are to: assess private sector accessibility of four
drugs used for uterotonic purposes (oxytocin, methylergometrine, misoprostol, valethamate bromide); and to assess
potency of oxytocin and methylergometrine ampoules purchased by simulated clients.
Methods: The study was conducted in Hassan and Bagalkot districts in Karnataka state and Agra and Gorakhpur
districts in Uttar Pradesh state. A sample of 877 private pharmacies was selected (using a stratified, systematic sampling
with random start), among which 847 were successfully visited. The target sample size for assessment of accessibility
was 50 pharmacies per drug, per district. The target sample size for potency assessment was 100 purchases each of
oxytocin and methylergometrine across all districts. Successful drug purchases varied by state.
Results: In Agra and Gorakhpur, 90%-100% of visits for each of the drugs resulted in a purchase. In Bagalkot and
Hassan, only 29%-52% of visits for each drug resulted in a purchase. Regarding potency, the percent of active
pharmaceutical ingredient was assessed using United States Pharmacopeia monograph #33 for both drugs; 193 and
188 ampoules of oxytocin and methylergometrine, respectively, were assessed. The percent of oxytocin ampoules
outside manufacturer specification ranged from 33%-40% in Karnataka and from 22%-50% in Uttar Pradesh. In Bagalkot
and Hassan, 96% and 100% of the methylergometrine ampoules were outside manufacturer specification, respectively.
In Agra and Gorakhpur, 54% and 44% were outside manufacturer specification, respectively.
Conclusion: Private sector accessibility of uterotonic drugs in study districts in Karnataka warrants attention. Most
importantly, interventions to assure quality oxytocin and particularly methylergometrine are needed in study districts
in both states.
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Postpartum hemorrhage (PPH) is the leading cause of
maternal death both globally and in India [1,2]. In India,
PPH deaths account for 31-38% of all maternal deaths [2].
The World Health Organization (WHO) recommends use
of a uterotonic drug for all births for the prevention of
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unless otherwise stated.prevention and treatment of PPH. Alternative uterotonics,
such as misoprostol and ergometrine are recommended
where oxytocin use is not feasible [3]. Current Govern-
ment of India guidelines also promote prophylactic use of
oxytocin, where feasible, or misoprostol for deliveries
attended by auxiliary nurse midwives through medical
officers [4,5]. Oxytocin and ergometrine have been
included in the WHO Model Essential Medicines List
since its inception in 1977; misoprostol was added to
the core list in 2005 [6]. More recently, all three drugs
appear in the Essential Interventions, Commodities andl Ltd. This is an Open Access article distributed under the terms of the Creative
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Child Health [7]. Oxytocin and misoprostol also figure as
two of only 13 drugs prioritized by the United Nations
Commission on Life-Saving Commodities for Women and
Children which proposes recommendations to address
not only limited access to these drugs but also interven-
tions to improve the their quality [8].
The quality of pharmaceutical medicines in general has
received increased attention globally from public health
professionals over the last decade. This is particularly true
in India given the increasingly important role India plays
as a drug exporter [9]. Globally, the predominant concern
regarding quality of medicines has been counterfeit drugs
[10,11]. However, the issue of substandard and/or degraded
drugs is also being recognized as a major public health
concern [12,13]. Given that distinct solutions are required
for each of these problems, Newton and colleagues have
stressed the need for a consensus on definitions and an
end to interchangeable use of these terms [14]. Globally
and in India, attention has focused primarily on anti-
infective drugs such as antiretroviral drugs, antibiotics,
anti-tuberculosis drugs and anti-malarials [12,15] Manu-
facturing to specific standards and monitoring of product
quality of such drugs is mandated as a prerequisite for
funding from international programs such as the Global
Fund to Fight AIDS, Tuberculosis and Malaria [16].
Regarding drug degradation, vaccine management is a
domain that has been highly promoted and supported
for several decades by the WHO-initiated Expanded
Program for Immunization, with an emphasis on cold
chain maintenance, equipment, training and monitoring
[17]. Consequently, for health care planners in infectious
disease, awareness of drug quality maintenance issues has
been a high priority for years.
The same is not true for health care planners in mater-
nal health. For example, despite pervasive global efforts to
prevent and treat postpartum hemorrhage via expanded
access to uterotonic drugs [18], particularly injectable oxy-
tocin and ergometrine which are heat-labile, similar efforts
have not been targeted toward uterotonic drug quality
management [8].
Until recently, most studies of uterotonic drug potency
dated from the 1990s. In 1993, a WHO simulation study
testing the stability of injectable uterotonic drugs showed
that after 12 months oxytocin lost no active ingredient
under refrigeration (4°–8° Celsius). Three-to-seven per-
cent active ingredient was lost after 12 months at 21°–25°
Celsius, and 9%–19% active ingredient was lost after
12 months at 30° Celsius. Oxytocin was not affected by
exposure to light. Ergometrine was shown to be much less
stable. Ergometrine lost 5% of its active ingredient after
12 months at 4°–8° Celsius (in darkness). When exposed
to light, it lost more than 90% of its active ingredient when
stored for 12 months at 21°–25° Celsius [19]. A few otherstudies were identified that assessed degradation of oral
and injectable uterotonics from environmental exposure.
In general, these studies supported the findings from the
WHO simulation that ergometrine was much less stable
under tropical conditions than oxytocin, and that both
posed public health concerns in contexts without access
to refrigeration [20-22].
In 2010, a uterotonic drug quality study was conducted
in three contrasting regions of Ghana in which research
assistants simulated clients, visited randomly selected
pharmacies, and requested to purchase two ampoules of
either oxytocin or ergometrine. All purchased ampoules
(n =101) were then sent for chemical assay to determine
the percent of active pharmaceutical ingredient (API) in
each ampoule. Results showed that 76% of the oxytocin
ampoules and 100% of the ergometrine ampoules were
outside manufacturer specification for API [23]. Post-
marketing surveillance which resulted from this study
found 39 of 40 (97.5%) and 38 of 40 (94.9%) injectable
oxytocin and ergometrine samples, respectively, failed the
assay for API or a sterility test. Ninety percent of the 118
ergometrine samples assessed in this surveillance exercise
were imported from India [24].
No published studies of uterotonic drug quality from
India were identified. In 2008, Bate and colleagues assessed
the concentration of active ingredient in 541 units of
ciprofloxacin, chloroquine, erythromycin, isoniazid and
rifampicin in pharmacies in New Delhi and Chennai
and found that 12% and 5% in each city, respectively,
failed the test [9]. Seear and colleagues tested units of
purchased rifampicin, artesunate and ciprofloxacin
from pharmacies in Chennai, India in 2010 and found
44%, 80% and 6%, respectively, of units to be outside of
manufacturer specification for API [25]; however, they
found no evidence of counterfeiting and concluded that
the poor quality drugs were likely due to poor manu-
facturing or decomposition during storage. Bate and
colleagues cite a 2003 report by the Indian government
which estimated that approximately 9% of all drugs sold
at pharmacies in India were of substandard quality [9].
A small unpublished study by Peter Hall at the Concept
Foundation of the quality of misoprostol tablets conducted
in eight low and middle income countries including India,
found problems with the content and purity of misoprostol
from some manufacturers. In 34 of 76 samples tested
across all eight countries, the active pharmaceutical ingre-
dient was less than 90% of the labeled content. A key
finding from this study is that appropriate packaging
with aluminum over and under the misoprostol tablets
(versus use of aluminum and plastic) is critical to its
stability by preventing exposure to humidity during stor-
age of the drug.
This study was designed as a sister-study to the Ghana
uterotonic drug quality study in order to provide an
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two diverse world regions. This study has two objectives.
The first objective is to assess the accessibility of four
drugs commonly used for uterotonic purposes from a
sample of private pharmacies in four districts in India.
The four drugs are: oxytocin, methylergometrine, miso-
prostol and valethamate bromide (brand name: Epidocin).
Valethamate bromide is not a uterotonic drug. It is a
smooth muscle relaxant which is commonly used in India
to relax the cervix and hasten delivery [26,27]. Here we
refer to it as a uterotonic. Unlike the other drugs studied
here, in this paper we refer to valethamate bromide by its
brand name which is highly recognized in contrast to its
nonproprietary name. The second objective is to assess
the potency of ampoules of oxytocin and methylergomet-
rine purchased by simulated clients. For this objective,
we focus only on uterotonics known to be in common
use during labor and the immediate postpartum period
in India.
Methods
To increase generalizability of results, two states (Karnataka
and Uttar Pradesh) with contrasting socio-economic indica-
tors were selected. Within each of these states, two districts
(Hassan and Bagalkot in Karnataka; Agra and Gorakhpur
in Uttar Pradesh) with contrasting maternal health indica-
tors were selected. Socio-economic and maternal health
indicators in Karnataka greatly surpass those in Uttar
Pradesh (Table 1). For example, literacy among women of
reproductive age and household electricity are substantially
higher and fertility is substantially lower in Karnataka than
in Uttar Pradesh [28]. The population of Uttar Pradesh
state is more than three times larger than that of Karnataka
(199.6 million vs 61.1 million in 2011), and Agra and
Gorakhpur combined are 2.4 times larger than Bagalkot
and Hassan [29,30]. Hassan and Gorakhpur are the
more rural districts of Karnataka and Uttar Pradesh,
respectively. Antenatal care and medical assistance at
birth are more than twice as high in Karnataka than
Uttar Pradesh [31].
The sampling plan for this study was nested within
the design of a parallel study in which a representative
sample of public health facility-based deliveries was
selected and observed, with an emphasis on documenting
uterotonic drug use before and after delivery of the baby
and other related behaviors by the birth attendant [34].
For the observation of deliveries study, the sampling
frame was restricted to public health facilities with at
least 72 deliveries per year, which eliminated 80 of the
203 facilities identified. Sixteen public health facilities
in each district were selected with probability proportional
to their annual volume of deliveries, for a total of 64 pub-
lic health facilities. The sampling frame for this uterotonic
drug accessibility and potency study includes all privatepharmacies surrounding those 64 public health facilities,
as pharmacies tend to cluster around health facilities in
India. The decision to incorporate the sample design of
the uterotonic drug accessibility/potency study into the
observation of deliveries study was made for two reasons:
1) women delivering in public facilities in India and in
many low income countries are asked to purchase
uterotonics at private pharmacies when facility stocks
are low; and 2) private pharmacies are a likely source of
uterotonics for women delivering at home, where unmon-
itored use of these drugs is common [32,33].
The size of this study was driven by the amount of fund-
ing available to test oxytocin and methylergometrine; we
gave each drug equal importance, and decided to split the
funds equally between the two, leading to a maximum
of approximately 200 assays for each drug, across all the
districts. This number was sufficient to estimate the pro-
portion of samples within API bounds with approximately
4%-7% precision, depending on the underlying true potency
rate (i.e. 90% to 50%, respectively). For analysis purposes,
two ampoules purchased from the same pharmacy is
considered as one unit for analysis. The purchase of
two ampoules per pharmacy was done to accommodate
possible breakage or the need to retest. To maximize the
sample available for subsequent within-district estimation
of the private sector accessibility of drugs, we decided
to achieve our per-drug pharmacy-visit target of 200 by
allocating an equal number of pharmacies per district
(50) to each drug. This sample size allows for construc-
tion of 95% confidence intervals of the overall, state,
and district-specific estimates of drug accessibility of
maximum width 7%, 10%, and 14% respectively (i.e. if
true accessibility is ~50%).
To compile the sampling frame of private pharmacies,
four teams of two research assistants and one field
supervisor set out on foot to list the name and address of
all pharmacies within one or five kilometers of selected
health facilities. The size of the study area surrounding
each health facility varied by the number of pharmacies
identified; in areas where fewer than five pharmacies were
found within one kilometer of the health facility, research
assistants expanded the perimeter of their search to five
kilometers. Once the sampling frame was completed,
study staff at headquarters then selected pharmacies for
the purchase of oxytocin by choosing a random start
number and systematically selecting pharmacies with a
constant sampling interval until reaching a sample of 50
pharmacies. The three consecutive pharmacies following
those selected for the purchase of oxytocin were selected
for the purchase of methylergometrine, misoprostol and
Epidocin, respectively.
Field staff were trained for 2.5 days to compile the
sampling frame of pharmacies, act as simulated clients,
document their purchases and assure that cold chain









Karnataka 61130 60.3 89.0 2.1
Uttar Pradesh 199581 43.0 43.0 3.8
District-level indicators
Population in '000 s in 2011 % rural % of births with ≥3
antenatal care visits
% of births with medically
trained attendant
Karnataka state
Bagalkot 1890 71.0 63.0 75.6
Hassan 1776 82.3 94.0 99.1
Uttar Pradesh state
Agra 4380 56.7 20.5 44.9
Gorakhpur 4436 80.4 43.3 43.6
Sources: [30-33].
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port of the purchased drugs. All field staff were male.
Trainings were conducted in Lucknow, Uttar Pradesh
and Bangalore, Karnataka. Staff from the Social Research
Institute, India, collaborated with the authors on training
and data collection. The sampling frame was compiled
during the month of July 2011.
Beginning in August 2011 in Uttar Pradesh and
September 2011 in Karnataka, research assistants vis-
ited their assigned pharmacies; each asked to purchase
the assigned drug for his sister or wife who was soon
to deliver. Research assistants assigned to purchase
oxytocin, methylergometrine or Epidocin attempted to
purchase two ampoules per visit. Those assigned to
misoprostol attempted to purchase three tablets, the rec-
ommended dosage for PPH prevention. When requested,
simulated clients provided an informal prescription which
consisted of a handwritten note bearing the logo of a
commonly used analgesic drug. Informal prescriptions
were prepared for human subjects purposes to avoid
putting the salesperson in the position of being asked
to sell drugs without a prescription even after he/she
had asked for one.
Shortly after leaving the pharmacy, research assistants
placed purchased ampoules or tablets in plastic bags with
coded labeling to identify the district, pharmacy, drug
purchased, form of the drug (ampoule or tablet) and
number of ampoules or tablets purchased. The plastic
bags were then placed in vaccine cold chain carriers
until the evening, at which point they were placed in
refrigerators, generally at the local health facility. Within
six weeks of data collection, all ampoules of oxytocin and
methylergometrine were transported in the cold chain to
VIMTA laboratory, a WHO pre-qualified laboratory, in
Hyderabad, India. VIMTA documented that all ampoules
were delivered under cold-chain conditions.Ampoules of oxytocin and methylergometrine were re-
frigerated until analysis at which point they were assayed
for the percent of active pharmaceutical ingredient (API).
Analysis was conducted following the Finished Pharma-
ceutical Product specifications of the United States
Pharmacopeia (USP) monograph #33 for both drugs. The
USP chemical reference standard (Batch No.: F2K133, Cat.
No.: 1491300) was used for oxytocin and the European
Pharmacopeia Chemical reference standard (Lot No.: 1,
Cat. No.: Y000076) was used for the analysis of methyler-
gometrine. Ampoules were tested without blinding to
product packaging, as this information is required for
testing. Due to requirements for ethical approval of the
study, manufacturer names are not reported.
Accessibility was estimated as the proportion of visits to
open pharmacies that resulted in a successful purchase of
the target drug. Similarly, prescription requirement was
estimated as the proportion of visits to open pharmacies
for which purchase of the target drug required a prescrip-
tion. Both proportions and corresponding exact binomial
confidence intervals were estimated separately for each
drug and district. For each of the assayed drugs (oxytocin
and methylergometrine), the relationship between API
and the time elapsed between manufacture and purchase
was initially assessed by examining locally weighted
scatterplot smoothing. As these plots indicated an
approximately linear relationship, both simple linear
regression and cubic spline models were estimated.
Analysis of residuals was utilized to assess for influen-
tial outliers, and after the removal of two points, the
predicted API from the final models were plotted
against the actual values. The absolute loss of API per
90 days elapsed was estimated, along with a 95% confi-
dence interval. Stata (Version 11) software was used
for data analysis. To note, we assume no further loss of
API from the point of data collection to assay given
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Ethics statement
There was no verbal or written informed consent for this
study, as consent of the salesperson would have under-
mined the simulated client methodology. The study proto-
col was approved by the following boards: Clinicom, the
state-level ethics committee in Karnataka; Chhatrapati
Shahuji Maharaj Medical University; Uttar Pradesh
Ethics Committee in Lucknow, Uttar Pradesh; the Health
Ministry Screening Committee and the Indian Council
on Medical Research in New Delhi; the PATH Research
Ethics Committee in Seattle, Washington, USA; and the
Johns Hopkins Bloomberg School of Public Health In-
stitutional Review Board in Baltimore, Maryland, USA.
In addition, the study was approved by the Directorates
of Health and Family Welfare in Karnataka and Uttar
Pradesh.
Results
Accessibility of uterotonic drugs
A total of 877 pharmacies were visited by simulated clients
across all four districts; 200 each in Agra and Gorakhpur,
Uttar Pradesh (as planned), 244 in Bagalkot and 233 in
Hassan, Karnataka. A total of 77 additional pharmacies
were selected after the beginning of fieldwork in Bagalkot
and Hassan due to the lower than expected availability
of oxytocin and methylergometrine there. All selected
pharmacies in Agra and Gorakhpur were open and visited
by simulated clients. In Bagalkot and Hassan, 14 and 16 of
the selected pharmacies, respectively, were closed during
the teams’ visits. In 847 pharmacies simulated clients were
able to speak with a salesperson.
Two aspects of accessibility of uterotonic drugs are
explored: the simulated client’s success at purchasing
the assigned drug and need for a prescription. Success
at purchasing assigned drugs varied significantly by
state, but in general, not between districts within the
same state. For example, in Agra and Gorakhpur, Uttar
Pradesh, 90%-100% of visits for each of the four drugs
resulted in a purchase. In Bagalkot and Hassan, Karnataka,Table 2 Percent (and exact binomial confidence intervals) of
was made by simulated clients by assigned uterotonic drug a
Bagalkot, Karnataka Hassan, Karnatak
P N % and 95% CI P N % and
Oxytocin 24 62 38.7 (26.6 – 51.9) 24 61 39.3 (2
Methylergometrine 23 77 30.0 (20.0 – 41.3) 23 69 33.3 (2
Misprosotol 16 43 37.2 (23.0 – 53.3) 23 44 52.3 (3
Epidocin 24 46 52.2 (36.9 – 67.1) 13 45 28.9 (1
Open private pharmacies 228 219
*one-sided 97.5% confidence interval.only 29%-52% of visits for each drug resulted in a purchase
and oxytocin and methylergometrine were successfully
purchased in only about one-third of visits. This may imply
a general lack of uterotonics in stock in private pharmacies,
low availability of these drugs in pharmacies given their
common availability in hospitals or suspicion by the sales
person leading to reluctance to sell to the simulated client
in Karnataka. The only significant difference in accessibility
of uterotonics between districts in Karnataka was for
Epidocin (Table 2). The need for informal prescriptions
varied by drug and by district (Table 3). Informal prescrip-
tions were requested in less than 10% of pharmacy visits
in Bagalkot and Hassan, Karnataka. In Agra, informal pre-
scriptions were rarely requested except for oxytocin. In
Gorakhpur, informal prescriptions were requested from
8%-44% of pharmacy visits depending on the assigned
drug; except for oxytocin, the need for a prescription was
higher in this district compared to the other three. In only
seven pharmacy visits (six in Hassan and one in Bagalkot)
was a prescription requested but no sale made. No add-
itional comments were provided by the simulated clients
to suggest that the cause was the informal prescription.
Drug potency
Table 4 presents the number of ampoules received at the
laboratory and analyzed by drug. A total of 193 ampoules
of oxytocin and 188 ampoules of methylergometrine were
received at the laboratory for testing. Three ampoules of
oxytocin in Hassan and four ampoules of methylergomet-
rine were reported purchased but not received at the
laboratory. Ampoules of oxytocin received at the labora-
tory were produced by 17 different manufacturers, nine in
Karnataka and eight in Uttar Pradesh. For methylergomet-
rine, parallel numbers are two and three manufacturers,
respectively. Although the study design required two
ampoules per pharmacy purchase as a unit of analysis, the
number of successful purchases in Bagalkot and Hassan,
Karnataka led to the decision to test all ampoules from
these districts. In Uttar Pradesh, only one ampoule per
sample was tested for API. The second ampoule, where
there was one, was held as a back-up in case of breakage;
20 ampoules of both oxytocin and methylergometrine cameopen private pharmacies at which a successful purchase
nd district
a Agra, Uttar Pradesh Gorakhpur, Uttar Pradesh
95% CI P N % and 95% CI P N % and 95% CI
7.1 – 52.7) 45 50 90.0 (78.1 – 96.7) 50 50 100 (92.9 – 100)*
2.4 – 45.7) 50 50 100 (92.9 – 100)* 48 50 96.0 (86.3 – 99.5)
6.7 – 67.5) 48 50 96.0 (86.3 – 99.5) 48 50 96.0 (86.3 – 99.5)
6.4 – 44.4) 50 50 100 (92.9 – 100)* 49 50 98.0 (89.4 – 99.9)
200 200
Table 3 Percent (and exact binomial confidence intervals) of attempts to purchase uterotonic drugs in which a
prescription was requested by assigned drug and district
Bagalkot, Karnataka Hassan, Karnataka Agra, Uttar Pradesh Gorakhpur, Uttar Pradesh
P N % and 95% CI P N % and 95% CI P N % and 95% CI P N % and 95% CI
Oxytocin 0 62 0 (0 – 5.8)* 3 61 4.9 (1.0 – 13.7) 10 50 20.0 (10.0 – 33.7) 4 50 8.0 (2.2 – 19.2)
Methylergometrine 3 77 3.9 (1.0 – 11.0) 4 69 5.8 (1.6 – 14.2) 2 50 4.0 (0.5 – 13.7) 11 50 22.0 (11.5 – 36.0)
Misprosotol 1 43 2.3 (0.1 – 12.3) 4 44 9.1 (2.5 – 21.7) 1 50 2.0 (0.1 – 10.6) 22 50 44.0 (30.0 – 58.7)
Epidocin 1 46 2.2 (0.1 – 11.5) 3 45 6.7 (1.4 – 18.3) 0 50 0 (0 – 5.8)* 13 50 26.0 (14.6 – 40.3)
*one-sided 97.5% confidence interval.
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Uttar Pradesh.
The percent distribution of the API in ampoules of
oxytocin and methylergometrine are presented by district
in Table 5. The percent of oxytocin ampoules outside
manufacturer specifications (90%-110% API) ranged from
33%-40% in Karnataka and from 22%-50% in Uttar
Pradesh. Small percentages of oxytocin ampoules showed
API from 110%-120%, and less than 11% of the ampoules
within any district showed oxytocin at 50% API or less.
The median API for ampoules of oxytocin across all four
districts ranges from 98.5%-102.9%. None of the ampoules
of oxytocin were expired at the time of testing.
Results for the potency of methylergometrine were less
favorable. In Bagalkot and Hassan, Karnataka 96% and
100% of the methylergometrine ampoules were outside
manufacturer specification, respectively. In Agra and
Gorakhpur, Uttar Pradesh 54% and 44% were outside
manufacturer specification, respectively. Likewise, median
API scores across all four districts were lower than those
for oxytocin, ranging from 84.4%-90.4%. None of the
methylergometrine ampoules were expired.
As mentioned above, the limited availability of oxytocin
and methylergometrine in the study districts in Karnataka
led to assaying all of the ampoules purchased there, in
contrast to UP where one ampoule was assayed perTable 4 Number of oxytocin and methylergometrine ampoule
Number of oxytocin ampoules rec
State/District
Karnataka state
Bagalkot 48 (2 each from 24 sites; all analyzed
Hassan 45 (2 each from 24 sites, missing 3; a
Uttar Pradesh state
Agra 50 (1 each from 36 sites providing pa
14 from sites providing 1 ampoule o
all analyzed)
Gorakhpur 50 (1 each from 40 sites providing pa
sites providing 1 ampoule only; all an
Total number of ampoules analyzed 193
Note: All ampoules received at the laboratory from Karnataka state were analyzed.
laboratory staff randomly selected one for chemical testing.pharmacy purchase in most cases. This design change
had little effect on the percentage of ampoules reported
as out of manufacturer specification, as the potency
results are nearly identical when both ampoules from
the same pharmacy are assayed. The absolute median
difference in the percent API among pharmacy-pairs of
purchased oxytocin and methylergometrine ampoules is
0.10% and 0.05%, respectively. This is not surprising as
the ampoules were likely from the same batch and
would have been exposed to the same environmental
conditions. Of 46 pharmacy-pairs of oxytocin ampoules
from Karnataka, in only five pairs was one within
manufacturer specification and the other outside speci-
fication. All 44 pharmacy-pairs of methylergometrine
ampoules were either both within or both outside
manufacturer specification.
Figures 1, 2, 3 and 4 plot the percent API for oxytocin
and methylergometrine by state and by time between
dates of manufacture and purchase of ampoules. The
negative slope of the regression lines for both drugs in
both states is supportive, but not proof, of environmental
degradation as an explanation for the API outside of
manufacturer specification. In Karnataka, for oxytocin
and methylergometrine, the approximate loss of API
per 90 days was 3.6% (1.6%-5.5%) and 2.3% (1.1%-3.5%),
respectively (Figures 1 and 2). In Uttar Pradesh, fors received and analyzed for chemical testing, by district
eived and analyzed Number of methyl-ergometrine
ampoules received and analyzed
) 42 (2 each from 23 sites, missing 4; all analyzed,)
ll analyzed,) 46 (2 each from 23 sites; all analyzed)
irs,
nly;
50 (1 each from 46 sites providing pairs, 4 from
sites providing 1 ampoule only; all analyzed)
irs, 10 from
alyzed)
50 (1 each from 40 sites providing pairs, 10 from
sites providing 1 ampoule only; all analyzed)
188
In Uttar Pradesh, in sites where two ampoules were provided per pharmacy,
Table 5 Percent distribution of Active Pharmaceutical Ingredient (API) in purchased ampoules of oxytocin and methylergometrine, by district
Karnataka state Uttar Pradesh state
Bagalkot Hassan Agra Gorakhpur








0%-25% 0.0 0.0 8.9 0.0 2.0 2.0 0.0 2.0
26-50% 0.0 9.5 2.2 0.0 6.0 2.0 0.0 0.0
51%-75% 4.2 7.1 4.4 13.0 14.0 8.0 2.0 6.0
76%-89% 27.1 83.3 22.2 82.6 16.0 42.0 10.0 36.0
WITHIN MANU-FACTURER
SPECIFICA-TION (90%-110%)
66.7 0.0 60.0 4.3 50.0 46.0 78.0 56.0
111%-120% 2.1 0.0 2.2 0.0 12.0 0.0 8.0 0.0
Missing data 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0
TOTAL 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
% Out of specification 33.0 100.0 40.0 95.7 50.0 54.0 22.0 44.0
Median API 98.5 84.4 98.7 85.8 99.0 89.2 102.9 90.4



















Figure 1 Karnataka: Measured Active Pharmaceutical Ingredient (in %) by time between drug manufacture and purchase; oxytocin.
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of API per 90 days was 6.4% (4.4%-8.4%) and 5.0%
(3.5%-6.5%), respectively (Figures 3 and 4).
Simulated clients recorded where the purchased am-
poules of oxytocin and methylergometrine were kept in
each pharmacy. See Table 6. In the districts in Uttar
Pradesh, oxytocin was kept unrefrigerated on the shelf
in 93% (Agra) and 100% (Gorakhpur) of pharmacies in
which oxytocin units were purchased. In the districts in
Karnataka, this practice is much less common, with
around 15% of pharmacies placing purchased oxytocin
ampoules unrefrigerated on the shelf, although not all
purchased ampoules were in view of simulated clients.Figure 2 Karnataka: Measured Active Pharmaceutical Ingredient (in %) bFor methylergometrine, 83% of pharmacies kept meth-
ylergometrine unrefrigerated on the shelf for purchase
in Gorakhpur, as did at least two-thirds of the pharmacies
in Agra.
Discussion
This study sought to assess accessibility of drugs com-
monly used for uterotonic purposes in India and to assay
the potency of oxytocin and methylergometrine available
in private pharmacies. In Uttar Pradesh, the simulated
clients documented easy access to all four study drugs.
In Karnataka, accessibility was much lower, implying a
possible lack of uterotonics in these districts, though wey time between drug manufacture and purchase; methylergometrine.
Figure 3 Uttar Pradesh: Measured Active Pharmaceutical Ingredient (in %) by time between drug manufacture and purchase; oxytocin.
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http://www.biomedcentral.com/1471-2393/14/386do not know if such shortages are frequent. Given the
small percentage of pharmacies requesting a prescription
in both states and the fact that informal prescriptions
used for this study sufficed 99% of the time, it appears
that weak enforcement of regulations for prescription
drugs permits easy access to uterotonic drugs in this
population.The potency of oxytocin and methylergomet-
rine varied by state, district and drug. However, even the
best-case scenario (in Gorakhpur, Uttar Pradesh) suggestsFigure 4 Uttar Pradesh: Measured Active Pharmaceutical Ingredient (
methylergometrine.that one in five ampoules of oxytocin available to the
population in private pharmacies may be outside manu-
facturer specifications for API. The worst-case scenario
for oxytocin was shown in Agra where one in two
ampoules of oxytocin was out of specification. Serious
problems were documented in the two study districts
in Karnataka where 96%-100% of methylergometrine
ampoules tested were outside manufacturer specification
for API. This is of particular concern as methylergometrinein %) by time between drug manufacture and purchase;
Table 6 Percent distribution of the placement of oxytocin and methylergometrine in pharmacies where these drugs





















Bagalkot 16.7 83.3 0.0 24 8.7 91.3 0 23
Hassan 12.5 79.2 8.3 24 30.4 39.1 30.4 23
Uttar Pradesh state
Agra 93.3 2.2 4.4 45 66.0 16.0 18.0 50
Gorakhpur 100.0 0.0 0.0 50 83.3 16.7 0.0 48
Total N 143 144
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tractions it produces. However, although API fell outside
quality thresholds for some proportion of both drugs,
fewer than 10% of the ampoules tested at 50% API or less.
None of the ampoules showed 0% API (one indicator of
a possible counterfeit drug) and none were expired at
the time of testing. No data are available to relate the
documented losses of API shown here for either drug
to clinical outcomes, though it is unlikely that any
Ministry of Health would endorse use of drugs out of
manufacturer specification. All results were shared with
the Ministry of Family Health and Welfare at the national
and state levels.
The strengths of this study include an up-to-date sam-
pling frame of private pharmacies compiled for the study
and a sample of oxytocin and methylergometrine that is
likely free of bias thanks to the simulated client method-
ology which prevents pharmacy staff from influencing
the selection of ampoules for assay. In addition, the
similarity of results regarding drug quality from four
contrasting sites suggests that uterotonic drug quality is
likely to be an issue in other districts of Karnataka and
Uttar Pradesh, and in other states in India. The MED-
QUARG checklist for field studies of medicine quality
developed by Newton and colleagues [13] was used in
designing and reporting on this study and is recom-
mended by these authors.
There are two limitations to this study. The first is that
sample size for potency testing was based on constraints
regarding the cost of the chemical assays. There is no
consensus on sample design for drug quality studies
[13,25]; detailed data on the volume and the flow of
drugs through private supply chains are difficult to
obtain, particularly in a country the size of India. In this
study in four districts, 17 different local manufacturers
of oxytocin were identified. However, these constraints
still provided us with high a-priori expected precision of
estimated API (i.e. 4% to 7% precision). The second limi-
tation is that interpretation of the drug potency resultsrequires caution. One cannot say why the drugs were out
of specification for API. Their potency at manufacture,
at departure from the manufacturer, or along the supply
chain is unknown. Although exposure to high temperatures
(oxytocin, methylergometrine) and light (methylergomet-
rine) likely contributed to the low APIs documented here,
it is curious that drug potency for methylergometrine
in Karnataka is worse than in Uttar Pradesh given that
higher percentages of these uterotonics were stored
outside refrigeration in Uttar Pradesh than in Karnataka.
On the other hand, the relationship shown in Figures 1, 2,
3 and 4 suggesting an approximate loss of API per 90 days
ranging from 3.6% to 6.4% for oxytocin and from 2.3% to
5.0% for methylergometrine, is highly suggestive of drug
degradation. The results of the assays for both drugs are
not suggestive of counterfeit drugs.
It is surprising that private-sector accessibility of utero-
tonic drugs and the potency of private-sector methylergo-
metrine were worse in Karnataka than in Uttar Pradesh
given the relatively advantaged status of Karnataka state.
Likewise, superior indicators in Gorakhpur relative to
Agra were not anticipated.
Conclusion
These results underscore the necessity of routine drug
surveillance and monitored pharmaceutical storage con-
ditions in the private sector. The status of uterotonic
drugs in the government health system is unknown. As a
result of this study, the protocol for a follow on study
assessing uterotonic drug potency in public health facilities
and the supply chain is currently underway in Karnataka
and Uttar Pradesh.
Development of a mini-lab kit for field-based assessment
of oxytocin, similar to kits in current use for antimicrobial,
antiretroviral, anti-tuberculosis and antimalarial drugs
[35], is urgently needed. Given that methylergometrine
is currently listed as a second-line drug for postpartum
hemorrhage prevention and treatment by WHO [3], and
that this is the second recent study to show the large
Stanton et al. BMC Pregnancy and Childbirth 2014, 14:386 Page 11 of 12
http://www.biomedcentral.com/1471-2393/14/386majority if not the entire sample of ergometrine/methyler-
gometrine ampoules outside of specification [23], a broader
discussion regarding the replacement of methylergomet-
rine/ergometrine with another drug or immediate attention
to storage conditions for this drug is warranted. Should
newer uterotonic drugs such as carbetocin and carbopost
become commonly available in India, an expanded assess-
ment of uterotonic drugs will also be warranted.
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